GENERAL COMMENTS
Firstly, I wish to congratulate to Dr Li et al. for this massive prospective study, which collects patient reported outcomes from patients treated with breast reconstruction or oncoplastic breast conservation surgery, as well as surgical outcomes and recurrence rates. It is likely to be the biggest in the world in its own field and is able to provide an excellent insight in the oncoplastic practice in breast cancer surgery in China. I note that the study has already been launched in its first phase. I would ask the corresponding author to clarify the following points in the manuscript: 1. I would suggest including the details of the registration for the revised manuscript on page 5. 2. Please clarify if each unit will enrol consecutive patients or randomly selected patients on page 9. 3. Collecting recurrence data during a 24 months follow-up is relatively meaningless. I advise the authors to include this fact either in the limitations on page 15 or in the secondary outcome section on page 10. 4. Please insert citation when "Chinese rules" mentioned on page 11. Also, the formal nomenclature should be givenif there is anyfor the same. Perhaps a somewhat detailed description should also be provided in this section, as "Chinese rules" holds no meaning for the foreign reader. I note the authors gained ethical approval from the Fudan University Shanghai Cancer Center. 5. Please clarify the opening paragraph of discussion on page 12 -13:
• only 5.66% of patients were treated with BCS between 1999 and 2008? • please explain by saying "surgical rate increased from 1.29% to 11.57% during the same period? Does this relate to BCS? • 10.7% patients underwent breast reconstruction or 4.5% had the same?
Again, congratulation for the major effort and I am looking forward to see the results in due course. It is likely to be the biggest in the world in its own field and is able to provide an excellent insight in the oncoplastic practice in breast cancer surgery in China. I note that the study has already been launched in its first phase. Answer: Thank you very much.
REVIEWER
I would ask the corresponding author to clarify the following points in the manuscript: 1. I would suggest including the details of the registration for the revised manuscript on page 5. Answer: Thank you very much for your suggestions. We have revised it according to your suggestion.
2. Please clarify if each unit will enroll consecutive patients or randomly selected patients on page 9. Answer: Thank you very much for your suggestions. We have revised it according to your suggestion.
3. Collecting recurrence data during a 24 months follow-up is relatively meaningless. I advise the authors to include this fact either in the limitations on page 15 or in the secondary outcome section on page 10. Answer: Thank you very much for your suggestions. We have revised it according to your suggestion. We added it as a limitation in our study. "Meanwhile, the follow-up of this study was 24 months, long enough for the PRO outcomes for patients with breast reconstruction, but short for the prognosis. Although this study was designed to follow-up about two years, we will keep eyes on the PROs and prognosis for a longer time. And for those patients in our center (Fudan University Shanghai Cancer Hospital), we have our own team for survival follow-up. So the long term survival data will be available for these patients. But for those patients in other centers, the long-term survival time was not available." 4. Please insert citation when "Chinese rules" mentioned on page 11. Also, the formal nomenclature should be givenif there is anyfor the same. Perhaps a somewhat detailed description should also be provided in this section, as "Chinese rules" holds no meaning for the foreign reader. I note the authors gained ethical approval from the Fudan University Shanghai Cancer Center. ANSWER: Thank you very much for your suggestions. We have revised it according to your suggestion. We removed "Chinese rules"in our study, as we have gained the ethical approval from the Fudan University Shanghai Cancer Center.
5. Please clarify the opening paragraph of discussion on page 12 -13: • only 5.66% of patients were treated with BCS between 1999 and 2008? Answer: Thank you very much for your suggestions. We have revised it according to your suggestion. This study calculated the number of patients who received BCS among all breast cancer patients, in order not to confuse readers, we decided to delete this sentence.
• please explain by saying "surgical rate increased from 1.29% to 11.57% during the same period? Does this relate to BCS? Answer: Thank you very much for your suggestions. We have revised it according to your suggestion. We revised it as "the BCS rate increased from 1.29% in 1999 to 11.57% in 2008".
• 10.7% patients underwent breast reconstruction or 4.5% had the same? Answer: Thank you very much for your suggestions. We have revised it according to your suggestion. We revised it as "However, only 4.5% patients underwent BR in 2012".
Again, congratulation for the major effort and I am looking forward to see the results in due course. Reviewer: 2 Reviewer Name: Andrzej Piatkowski, MD PhD Institution and Country: Department of Plastic Surgery MUMC+ Maastricht The Netherlands Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below Except for a couple of smaller language issues the manuscript is well written and acceptable. The study-design is very good. There are well points concerning the documentation of the cosmetic result. A simple frontphotography will not show all the problems concerning cosmesis. A 3/4 angled view from both sides should be added. Answer: Thank you very much for your suggestions. We have revised it according to your suggestion. We revised it as "Picture of the patients (anterior, lateral, 3/4 angled view from both sides) will be taken with the patients hands on the hips"
